| Abstract:Objective To investigate the effects of Dulotide on liver fat and fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease (NAFLD). Methods A total of 85 patients with type 2 diabetes combined with NAFLD who were treated in the Department of Endocrinology, Gongli Hospital Pudong New Area, Shanghai from July 2021 to July 2022 were selected as the study objects. The body mass index (BMI), neck circumference, waist circumference and hip circumference of the patients were observed after one year of use of Dulotide. Visceral fat content (VFV), subcutaneous fat content (SFV); blood glucose index (fasting blood glucose [FBG], fasting C-peptide [C-P], fasting insulin [FINS], glycated hemoglobin [HbAlc]); liver function indicators (alanine aminotransferase [GPT], glutamic oxalic aminotransferase [GOT], γ-glutamyltransferase [γ-GGT], alkaline phosphatase[ALP] albumin [ALB]); changes of lipid indexes (cholesterol [TC], triglyceride [TG], high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C], free fatty acid [FFA], hepatic steatosis index [HSI], fatty liver index [FLI]), aspartateaminotransferase to platelet ratio index (APRI) score, and NAFLD fibrosis score (NFS) were observed before and after use of Dulotide. Results The BMI, waist circumference, and hip circumference after treatment were lower than those before treatment, and the differences were statistically significant (P＜0.05). After treatment, FBG and HbA1c were lower than before treatment, the differences were statistically significant (P＜0.05), while CP and FINS were not statistically significant compared with before treatment (P＞0.05). After treatment, FFA was lower than before treatment, HDL-C was higher than before treatment, the difference was statistically significant (P＜0.05). There were no significant differences in TG, TC and LDL-C before and after treatment (P＞0.05). After treatment, GPT and GOT were lower than before treatment, and the difference was statistically significant (P＜0.05). There were no signifiant differences in the ratios of γ-GGT, ALKP, ALB and GOT/GPT before and after treatment (P＞0.05). After treatment, VFV， PC, and SFV were lower than before treatment, and the differences were highly statistically significant (P＜0.001). After treatment, the FLI index, HSI index, APRI score, and NFS score of liver fat were lower than those before treatment, and the differences were statistically significant (P＜0.05). There was no significant difference in FIB-4 before and after treatment (P＞0.05). Conclusion Dulaglutide can improve the metabolic status, liver fat, and liver fibrosis in T2DM with NAFLD patients. |
